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Background: Antipsychotic clinical trials use to present adverse events (AEs) for the
drug under evaluation to treat schizophrenia. Interestingly, patients who receive the
placebo during antipsychotic trials often report several AEs, but little is known about
the essence of these negative effects in patients with schizophrenia spectrum disorders
(SCD). In the present meta-analysis, we evaluated the relationship between the level
of psychiatric symptomatology expressed as Positive and Negative Syndrome Scale
(PANSS) scores and the rates of AEs reported in the placebo arms of double-blind clinical
trials, for commonly prescribed atypical antipsychotic medications.
Methods: We selected 58 clinical trials describing AEs in SCD placebo groups,
which compared atypical antipsychotic medications with placebo. A total of 6,301
placebo-treated patients were considered. AE profiles of the class were clusterized using
MedDRA classification and analysed using a meta-regression approach.
Results: In the placebo arms the proportions of patients with any AE was 66.3%
(95% CI: 62.7–69.8%). The proportion of withdrawal of patients treated with placebo
because of AEs was 7.2% (95% CI: 5.9–8.4%). Interestingly, the AEs in the placebo arms
corresponded to those of the antipsychotic-atypical-medication-class against which the
placebowas compared. Namely, usingmeta-regression analysis we found an association
between the level of psychiatric symptomatology measured with PANSS scores and
higher AEs reported as nervous system (p = 0.020) and gastrintestinal disorders
(p = 0.004). Moreover, the level of a higher psychiatric symptomatology expressed
with PANSS scores was also related with higher AEs associated with psychiatric
symptoms (p = 0.017).
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Conclusion: These findings emphasise that the AEs in placebo arms of clinical trials
of antipsychotic medications were substantial. Importantly, a higher level of psychiatric
symptomatology makes SCD patients more prone to express AEs, thus contributing to
possible drop-outs and to a lower adherence to treatments. These results are consistent
with the expectation theory of placebo and nocebo effects.
Keywords: schizophrenia, randomized clinical trials, placebo, nocebo effects, adverse events, atypical
antipsychotic drugs, expectation theory
INTRODUCTION
Adverse events (AEs) in pharmacological treatments of
psychiatric disorders are something that significantly affect
the adherence and the drop-outs of patients (Wahlbeck
et al., 2001). Many AEs are directly derived from the specific
pharmacological actions of an antipsychotic drug. It is well-
known that different peculiar AEs are caused by different
specific antipsychotics (Stroup and Gray, 2018). For example,
in the treatment of schizophrenia spectrum disorders (SCD),
different pharmacological agents can be used. In recent years
clinicians have progressively treated schizophrenia using
atypical (or second-generation) antipsychotics in preference to
“conventional” typical (first-generation) drugs (Crossley et al.,
2010). These two different class of drugs induce different rates of
AEs. Typical antipsychotic drugs are associated with higher risk
for extrapyramidal symptoms (EPS) and cognitive impairment.
In contrast, atypical forms show better adverse event profiles
and have a lower incidence of drug-induced EPS, compared with
the other class (Lehman et al., 2004). However, patients treated
with atypical drugs frequently report a number of AEs such
as: seizures, sedation, orthostatic hypotension, anticholinergic
effects, weight gain, prolactin increases, hepatic changes, and
agranulocytosis (Meltzer, 1998).
Hwang et al. (2010) suggested that unfavorable treatment
related expectation effects≪might result in certain psychological
and somatic symptoms (Barsky et al., 2002; Benedetti et al.,
2006; Reeves et al., 2007), a phenomenon largely studied as
nocebo effect. . . If the nocebo concept for the understanding
of the interaction between psychopathology and subjective
side effects is adopted, it could be hypothesized that certain
psychopathological conditions might make patients more prone
to a negative treatment expectation, which may in turn adversely
affect their subjective experience and evaluation of side effects≫
(pp. 83–84). It has been seen that depression, anxiety, and a
tendency to somatize (Barsky et al., 2002), seem to be linked
with the nocebo phenomenon observed in placebo groups of
RCTs and/or through the reports of non-specific side effects
with active medications (Hwang et al., 2010). It is plausible
that the level of psychopathology in patients with psychiatric
disorders widely affected their perceptions and attribution of
the bodily sensations toward medications (Hwang et al., 2010);
however, to our knowledge, no studies have investigated how
that turns into the subjective report of AEs in patients with
SCD, using a meta-analysis approach. Interestingly, only one
study investigated the relationship between psychopathology and
subjective AEs showing that self-reported side effects in patients
with schizophrenia may be influenced by the severity of positive
symptoms, and signs of anxiety and depression. Essentially, the
results of the study indicated that positive symptoms not only
directly affect subjectively reported AEs, but also affect them
indirectly by influencing anxiety symptoms (Hwang et al., 2010).
The authors concluded that schizophrenic patients, with high
levels of positive and anxiety/depressive symptoms, may be more
susceptible to nocebo-like-effects of antipsychotics.
In a classic clinical trial, participants know they can receive
either the active medication or the placebo and, accordingly,
they are informed about the possible AEs they may experience
during the trial (Amanzio et al., 2016). Different studies on
both placebo and nocebo effects have shown that expectations
about the therapeutic outcome play a critical role in the response
to treatment (Kirsch, 1985; Amanzio et al., 2001; Benedetti,
2008; Enck et al., 2008; Price et al., 2008). This applies to both
positive suggestions leading to positive outcomes and negative
suggestions bringing to a worsening of symptoms, as in the case
of nocebo-like-effects. Therefore, informing subjects about the
possible AEs they may experience, may have a significant impact
on their expectations of negative effects (Amanzio et al., 2016).
In line with these considerations, we conducted the first study
that analysed randomized clinical trials of three different classes
of anti-migraine medications (non-steroid anti-inflammatory
drugs, triptans and anticonvulsants) that reported rates of AEs
in placebo groups (Amanzio et al., 2009). We demonstrated
that the AEs in the placebo groups corresponded to those of
the anti-migraine medication against which the placebo was
compared. Moreover, the number of AEs in the placebo arms
of trials with anti-migraine drugs was high. Similar results were
obtained in a systematic review that considered nocebo effects
for antidepressant placebos comparable to the AE-profiles of
different classes of tricyclic antidepressants (Rief et al., 2009).
These key results are not consistent with the belief that nocebo
effects were simply non-specific.
The present study represents the first meta-analysis of nocebo-
like-effects in SCD patients. We evaluated AEs in placebo treated
patients in RCTs of atypical antipsychotic drugs. Our hypothesis
was that the placebo-related-AEs may corresponded to those
associated at the atypical antipsychotic class. Moreover, we
considered the role of the level of psychiatric symptomatology
in experiencing AEs. Namely, we expected increased rates of
AEs associated to higher scores of the Positive and Negative
Syndrome Scale (PANSS: Kay et al., 1987). Indeed, as an
objective measurement of psychopathology, PANSS offers an
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assessment of a comprehensive range of symptom domains
in SCD through positive, negative and general symptoms
subscales. We hypothesized that the severity of illness may make
patients more prone to developing distressing symptoms related
with treatments.
MATERIALS AND METHODS
Study Selection
We embraced the definition of meta-analysis accepted by the
Cochrane Collaboration (Green et al., 2008) and the “PRISMA
Statement” international guidelines in order to guarantee a see-
through report of our data selection procedures (Liberati et al.,
2009; Moher et al., 2009). A systematic search strategy was
implemented to identify relevant SCD studies, published until
1 March 2018, across the online database most frequently used
in the international literature (Medline database with PubMed
literature search: http://www.ncbi.nlm.nih.gov/pubmed). All the
articles that did not meet the inclusion criteria were excluded.
With this aim, we reviewed the relevant literature in order
to ensure: (1) the inclusion of either the healthy control
group and the pathological sample (patients with SCD);
(2) randomized, double-blind, placebo-controlled and parallel
design; (3) administration of commonly prescribed atypical
antipsychotic medications or experimental drugs with an atypical
antipsychotic profile for SCD; (5) report of placebo related AEs;
(6) the original diagnosis made on the basis of DSM criteria and
clinical test batteries; and (7) that the studies were original works.
Instances of multiple references to the same data sets across
articles were identified so as to make sure that only one reference
to the same data contributed to the present meta-analysis [see
Table S1,Appendix 1 in the Supporting Information and Prisma
Flow Chart in the main text (Figure 1)].
Specifically, three of the authors screened titles/abstracts of all
identified articles. Subsequently, two authors authors examined
the full texts independently (double-blind) and according to the
pre-defined eligibility criteria. The full text that have not been
found were requested by mail. The use of the same investigators
to accomplish selection ensured both consistency between the
selected studies and the only inclusion of RCTs that optimally
defined the target population of patients and the placebo arm.
Significantly, investigators who carried out this research stage
FIGURE 1 | PRISMA flow chart.
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have reached substantial agreement (% of agreement 96.50655;
Cohen’s K 0.50192).
While we were in the selection phase, we found few studies
that analysed placebo treated patients in RCTs of typical
antipsychotic drugs, this unfortunately made it impossible to
compare the two pharmacological classes (typical and atypical)
considering the respective placebo groups.
Two authors independently conducted data-extraction
and performed the assessment of methodological quality.
Disagreements that occurred in these phase were solved through
discussion between all authors. The Cochrane Collaboration’s
tool for assessing risk of bias (Higgins and Altman, 2008;
Higgins et al., 2011) was used to ascertain the validity of
eligible studies. Six domains were assessed for each study: (1)
sequence generation (selection bias); (2) allocation concealment
(selection bias); (3) blinding of personnel and outcome assessors
(performance bias); (4) blinding of outcome assessment
(detection bias); (5) incomplete outcome data (attrition bias);
and (6) selective outcome reporting (reporting bias). The
domains “incomplete outcome data” and “selective outcome
reporting” were separately assessed for patients withdrawing
because of AEs and occurrence of AEs (including serious AEs).
Considering the pharmacological treatment, drugs considered
eligible to enter in our database were: Amisulpride, Aripiprazole,
Asenapine, Bifeprunox, Brexpiprazole, Cariprazine, Fananserin,
Iloperidone, Lumateperone (ITI-007), Lurasidone, Olanzapine,
Paliperidone, Quetiapine, Risperidone, Sertindole, Vabicaserin,
Ziprasidone, and Zotepine. Studies comparing two different
classes of anti-psychotic drugs (i.e., typical and atypical) in the
same trial were excluded.
Outcomes Measures Search
Outcome measures were retrieved from tables reporting AEs
or from the main text of each selected original article. Data
were extracted in the same way as it has been done in previous
meta-analyses by our group (Amanzio et al., 2009; Giovannelli
et al., 2015; Zaccara et al., 2015). Briefly, for each study we
extracted: (a) the number of randomized patients (intent-to-
treat population, ITT); (b) the total number of AEs reported in
placebo treated patients (c) the number of patients withdrawing
because of AEs and PANSS score. AEs were categorized into
three groups based on MedDRA classification (Brown et al.,
1999) codified as: (1) nervous system disorders; (2) psychiatric
disorders and (3) gastrointestinal disorders. We considered few
terms as synonymous of the considered AEs. For details on
synonyms, see Table S2.
Data Analysis
Statistical analyses were performed using SPSS version 25.0 (IBM
Corp, 2017) for Windows. Data for the principal demographic
and clinical characteristics (PANSS) are expressed as range,
percentage or the mean± standard deviation.
Proportions of patients randomized to placebo arm with
95 % confidence intervals (CIs) have been expressed for all
reported outcome measures. The meta-analysis was conducted
using the software Open Meta-Analyst (Wallace et al., 2009).
Heterogeneity between studies has been assessed by I2 and
TABLE 1 | Characteristics of the placebo arm group (meta-sample for our
meta-analysis).
% range Mean (±SD) Range
Sample size (n = 6301) 22–207
Male (%) 67.6%
Female (%) 32.4%
Age (years) 39.78 (±5.17) 24.4–69
PANSS Total score 87.2 (±15.08) 43.1–104
PANSS, Positive and Negative Syndrome Scale; SD, Standard Deviation.
Cochrane Q test. A random effects model has been used due to
heterogeneity among studies.
A weighted least squares meta-regression has been performed
to explore the effect of multiple factors (i.e., year of publication,
number of study arms, duration of study and severity of
disease) on the selected outcome measures (total number of AEs,
withdrawal for AEs, nervous system disorders, gastrointestinal
disorders and psychiatric disorders). The mean PANSS score has
been used to evaluate the relationship between disease severity
and AEs. The meta-regression model has been weighted by the
inverse of variance of each study. When the above-mentioned
data were not found, we excluded the original research from
the meta-regression analyses of that data. In the meta-regression
analysis significance was set at p < 0.05.
RESULTS
Selection Outcome
Fifty eight RCTs were included in the analysis (1 for Amisulpride,
8 for Aripiprazole, 3 for Asenapine, 1 for Bifeprunox, 3
for Brexpiprazole, 5 for Cariprazine, 1 for Fananserin, 1 for
Iloperidone, 1 for Lumateperone (ITI-007), 7 for Lurasidone,
4 for Olanzapine, 12 for Paliperidone, 3 for Quetiapine, 2 for
Risperidone, 1 for Sertindole, 1 for Vabicaserin, 3 for Ziprasidone,
and 1 for Zotepine).
Characteristics of Eligible Trials
The main features of the 58 RCTs selected for the statistical
analyses are reported in Table 1. In the selected RCTs, 6,301
patients were treated with placebo. Sample size of patients treated
with placebo varied across trials from a minimum of 22 to a
maximum of 207 patients. Mean duration of all double-blind
period (titration plus maintenance) (mean ± SD) was 12.78 ±
14.6 weeks (range 1–52 weeks).
Risk of Bias Validity of Eligible RCTs
Risk of bias of the included studies is shown in Figure 2.
For the selection bias, allocation concealment was the more
poorly reported domain with 27 studies (47%) being judged
to have an unclear level of risk; 13 studies (22%) were
judged to have an unclear risk in the random sequence
generation domain.
Regarding performance and detection biases, most
information is from studies at low or unclear risk: 33
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FIGURE 2 | Assessment of the risk of bias in included studies. The judgement for each entry involves assessing the risk of bias as “low risk,” as “high risk,” or as
“unclear risk,” with the last category indicating either lack of information or uncertainty over the potential for bias.
TABLE 2 | Proportion (95 % CI) of patients treated with placebo from 58 double-blind, placebo-controlled studies performed in patients with schizophrenia spectrum
disorder for each outcome measures.
Number of
events
Total number of patient
in the placebo arm
PR (%) 95% CI (%) Heterogeneity
I2 Cochran’s Q test
Withdrawal for AEs 518 6097 7,2 (5.9, 8.4) 84% <0.001
All AEs 3621 5523 66,3 (62.7, 69.8) 88% <0.001
Nervous system disorders 1596 6281 27,6 (22.9, 32.2) 97% <0.001
Psychiatric disorders 1929 6298 30,4 (24.8, 36.0) 98% <0.001
Gastrointestinal disorders 693 5370 12,9 (10.8, 15.0) 93% <0.001
AEs, Adverse Events; CI, Confidence Interval; PR, Proportion.
(57%) and 29 (50%) studies, respectively, were judged to
have an unclear level of risk as insufficient information
were provided.
For the attrition and reporting biases, separately assessed for
patients withdrawing because of AEs and occurrence of AEs
(including serious AEs), most information is from studies at
low risk.
Nocebo Like Effect in RCTs
Table 2 report the number of placebo-treated patients
withdrawing due to AEs, the total number of patients who
had experienced AEs and the number of side effects for the 3
selected classes of AEs.
Heterogeneity was generally high. In particular, the
proportion of AEs reported varies between 0.02 and 17%
depending on the side effect considered. Table 3 report the
proportions of subjects who had experienced each of the selected
AE for each of the three conditions assessed.
In general, nervous system and psychiatric disorders AEs
were significant associated with higher score on PANSS scale.
Moreover, patients with a higher degree of psychiatric AE-
symptoms achieved higher scores on PANSS scale (see Table 4).
The association between PANSS and the three selected AEs
groups were expressed by an inverse of variance-weighted linear
meta-regression model in Figure 3. Meta-regression revealed
significant relationship among the symptom severity of SCD
patients and the considered AEs.
DISCUSSION
As previously reported by Amanzio (2015), ≪in double-blind,
randomized clinical trials, the AEs reported in placebo-treated
groups are not associated with a pharmacological treatment,
but other factors should be taken into account to explain
these symptoms. This phenomenon may be conceptualized
as “nocebo-like-effects” relating to negative expectations for
treatment outcome, even though a role of prior learning in the
form of conditioning with active treatments cannot be excluded.
This approach makes it possible to observe how associating
the placebo groups with a particular drug can cause specific
AEs that are consistent with those observed in the active
group≫ (page 159).
Before ingoing the double blind arm of a treatment trial,
the examiner’s instructions about the possible AEs associated
with a specific antipsychotic drug may affect the outcomes
(Amanzio et al., 2009). In particular, behaviors manifested
by health care providers and verbal suggestions are likely to
vary significantly across research contexts and may accordingly
generate significant variability in nocebo-related AEs (Amanzio
et al., 2016). Specifically, if the active treatment is denoted as
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TABLE 3 | Adverse events in the placebo arm experimental group.
N
NERVOUS SYSTEM DISORDERS
Akathisia 240
Ataxia 0
Attention difficulties 0
Back pain 40
Cogwheel rigidity 1
Diplopia 1
Dizziness 118
Diskynetics events 1
Dystonia 3
Epilepsy 2
Extrapyramidal disorders 91
Headache 620
Hyperkinesia/hypertonia 31
Language difficulties 0
Memory impairment 0
Myalgia 7
Pain 89
Paresthesia/tingling 18
Parkinsonism 2
Sedation/somnolence 282
Tremor 50
PSYCHIATRIC DISORDERS
Abnormal thinking 295
Agitation 324
Aggressive reaction/behavior 6
Anxiety 312
Apathy 6
Depression 16
Hostility 4
Insomnia 713
Nervousness 22
Psychosis 231
GASTROINTESTINAL DISORDERS
Abdominal pain 14
Diarrhea 75
Dry mouth 20
Dyspepsia 178
Nausea 182
Vomiting 178
Toothache/tooth disorders 46
AEs, Adverse Events; N, number of patients reporting symptoms.
an atypical antipsychotic, the examiner may imply that patients
will experience those AEs that are in line to this class of drugs
(Haddad and Sharma, 2007). For example, and considering the
three drugs most represented in our meta-analysis (information
obtained from Food and Drug Administration, FDA):
• Paliperidone: abdominal pain, back pain, blurred vision,
bradykinesia, constipation, diarrhoea, dizziness, dry mouth,
dystonia, fatigue, headache, hypotension, insomnia, muscular
stiffness, musculoskeletal pain, nasal symptoms, nausea,
parkinsonism, pharyngitis, rash, restlessness, salivation
increased, irregular heartbeat, somnolence, tremor vomiting.
• Aripiprazole: constipation, diarrhoea, dizziness, headache,
heartburn, increased appetite, increase salivation, pain,
weight gain.
• Lurasidone: abdominal pain, anxiety, dizziness, dry mouth,
extrapyramidal disorders, insomnia, muscle stiffness, nausea,
rash, restlessness, salivation increased, somnolence, vomiting.
Indeed, patient’s inauspicious antipsychotic-related expectations
and effect might result in certain somatic and psychological
symptoms. Rief et al. (2009) previously described this
phenomenon through their systematic review examining
placebo AEs in tricyclic antidepressant randomized clinical
trials. The authors depicted nocebo effects in antidepressant
placebos similar to the AE profiles of the real drugs, which they
were matched with (Rief et al., 2009). Moreover, AEs may also
be due to other factors such as the level of psychopathology
observed in SCD patients. Interestingly, psychopathology—such
as severity of depressive/anxiety or positive symptoms - adversely
affected self-reports of AEs in this kind of patients (Hwang et al.,
2010). Importantly, although the patients’ neuropsychosocial
profile is little analysed in RCTs, it is likely to be operating in
nocebo effects in those patients with reduced global executive
functioning (Kim et al., 2002; Hwang et al., 2009). It may
be hypothesised that cognitive impairments at the level of
the processes involved in the generation of precise spoken
definitions, such as auditory-verbal working memory, generative
ability, oral fluency and semantic retrieval (Lezak et al.,
2004), may be also responsible of subjective over-generalizing
discomfort. We observed these aspects in studding the placebo
arms of donepezil trials (Amanzio et al., 2012). Indeed, we found
Alzheimer’s disease patients to be at a superior risk of developing
AEs than subjects with a mild cognitive impairment.
The present study represents the first meta-analysis aiming
to underline the presence of nocebo-like AEs in placebo
groups matched with an antipsychotic atypical drug in the
SCD treatment. We have found that 65.5% of the patients
treated in placebo arms of trials described AEs and 8.5%
therefore discontinued the treatment. Interestingly, our meta-
regression approach demonstrated a relationship between the
frequency of AEs at nervous system and gastrointestinal levels
and higher PANSS score. Indeed, a higher level of psychiatric
symptomatology is associated with a tendency to over-report
specific AEs, thereby making patients, who suffer most from
their psychiatric symptoms,more prone to developing distressing
events related with treatments (Hwang et al., 2010). Therefore,
patients with severe levels of depressive/ positive and anxiety
symptoms may be sensible to antipsychotics nocebo-like effects,
as previously shown by a study by Hwang et al. (2010).
A possible explanation is that of a negative outcome risk
possibly related with the presence of a chronic disease. Research
works concerning the evaluation of AEs and tolerability of
antipsychotics should benefit by considering the implication of
these findings. Above all, it would be advisable to follow better
the treatment adherence in the presence of AEs not only in the
acute phase but also after symptoms stabilization.
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TABLE 4 | Results of meta-regression analysis.
Year of publication Number of study arms Duration of the study PANSS Score
P R P r P r P r
Withdrawal for AEs 0.542 0.083 0.029 0.292 0.169 0.190 0.091 0.264
All AEs 0.308 −0.149 0.125 0.222 0.290 −0.158 0.052 0.318
Nervous system disorders 0.056 −0.255 0.499 0.091 0.521 −0.088 0.020 0.359
Psychiatric disorders 0.189 −0.177 0.005 −0.369 0.002 0.416 0.017 −0.367
Gastrointestinal disorders 0.961 −0.007 0.158 0.205 0.884 0.021 0.004 0.460
The effect of 4 factors (year of publication; number of study arms; duration; and PANSS score) on reported outcome measures were analyzed. P-values and r coefficients are given.
AEs, Adverse Events; PANSS, Positive and Negative Syndrome Scale.
FIGURE 3 | Relationship between percentage of Adverse Events and PANSS total score estimated by an inverse of variance-weighted linear meta-regression model
(bubbles represent the inverse of variance). (A–C) which represent the AE related to the PANSS score.
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It is worth noting that the AE profiles reported in
the clinical trials presented in this meta-analysis are not
influenced by possible impact factors such as the year of
publication, the number of study arms and the duration of
the study. Since we specifically wanted to analyse possible
effects of suggestions related with research contexts, our
meta-analysis did not include a trial design comparing two
different classes of antipsychotic pharmacological treatment
or crossover trials. Actually, the possible contribution of
pharmacological conditioning in crossover RCTs could represent
a confounding factor.
As previously reported by Meister et al. (2017, p. 296) some
possible limitations of the meta-regression approach need to be
also mentioned: (1) it may generate false-positive associations
that reflect no real associations, but are caused by chance
alone (Higgins and Thompson, 2004); (2) by conducting meta-
regression analyses based on aggregated data of primary trials,
we can only draw inferences on a study level and not on an
individual level (Berlin et al., 2002; Rabinowitz et al., 2016).Meta-
regression analyses on individual data may consequently result
in different results; (3) it do not allow causal interpretation of
the results; (4) we only conducted univariate but not multivariate
meta-regression analyses due to power considerations. By fitting
univariate models only, we could not simultaneously control
for other modifiers; (5) the number of the included trials limit
our results just like the fact that the analyzed pool of studies
were heterogeneous concerning the sample clinical features such
as gender and age. However, meta-regression analyses revealed
hardly any association between these characteristics and the
outcome rates; (6) we included only trials that investigated
adults (age range 24.4–69). Certainly, our results may not
be transferable to younger populations (e.g., children and
adolescents). (7) Our analyses could only be dropped on the total
PANSS score. This can be reductive. As previously reported by
Hwang et al. (2010) some PANSS factors (delusion, hallucination,
suspicion/persecution, and unusual thought content) produce
misattributions of bodily sensations that directly contribute to
over-generalized reporting of AEs.
An important source of bias could have emerged from the
evaluation of the risk of bias (Higgins et al., 2011). Considering
the purposes of our work, blinding of personnel and outcome
assessors (performance bias) and blinding of outcome assessment
(detection bias) are particularly important. These are also the
most critical domains because in about half of the studies we
have given an evaluation of “Unclear risk”. This could have
led to a possible bias in the results and, consequently, in
their interpretation.
We here highlight methodological shortcomings with the aim
of suggesting how the detection and reporting of AEs can be
improved in future RCTs. The insights from our current study
should be considered when designing clinical trials to tailor
individualized treatments. Our results emphasize the importance
of outlining standardized detection procedures for collecting
relevant data in randomized, double-blind, placebo-controlled
trials of drug efficacy in patients with SCD. In particular, adequate
methodology, planning and execution are critical issues in RCTs
of psychiatric patients (Porter et al., 2003).
On the basis of the general nocebo effect literature of
the specific disease we have analysed, it will be possible to
hypothesize standardization of procedure in clinical trial designs
through methodological shortcomings, which may contribute to
tailoring individualized treatment: (1) appropriate assessment
strategy of AEs, (2) putative patient-related psychological-
psychiatric factors and baseline characteristics, and (3)
behaviours and verbal suggestions manifested by medical
staff and researchers. Importantly, a complex and not yet
developed integrated approach to the study of these combining
factors would be required to clarify the presence of psychological
distress predisposing patients to report nocebo-related AEs to
an even greater extent (Amanzio et al., 2012). We previously
hypothesized this kind of a more accurate assessment in
neurological patients with chronic disease, but these conclusions
may also be applied in the psychiatric population. Specifically,
as Häuser et al. stated 2012, specific strategies to reduce nocebo
effects should be further developed in clinical trials and practice
to minimize these symptoms (Enck et al., 2013), also considering
patients with SCD. As we have previously reported (Amanzio,
2015), ≪Rief et al. (2009) rightly observed that drug trials
should consider the base rates of pre-existing general complaints
more rigorously in the population being studied≫ (page 160),
to distinguish drug-associated AEs from the general base
rates of symptoms represented by patients’ characteristics in
terms of significant mood changes in terms of depression and
anxiety, tendency to catastrophizing, prior experiences with AEs,
pre-existing symptoms and the tendency toward somatization,
symptom amplification and selective attention on bodily
sensations; all of which were associated with nocebo effects
(Wolf and Pinsky, 1954; Andrykowski and Redd, 1987; Barsky
et al., 2002; Nestoriuc et al., 2010). Moreover, neuropsychosocial
factors, such as general cognitive impairment and executive
dysfunction that may influence AE experience should also be
assessed (Kim et al., 2002; Hwang et al., 2009; Amanzio et al.,
2012). It would also be important to collect data on prior
therapies that were not successful to identify those patients who
have a possible history of medically unexplained complaints
in the recruitment phase of RCTs that could compromise
adherence to treatment. Importantly, patients who are most at
risk of developing nocebo-like AEs should be identified through
assessing the above-mentioned variables; for an example of a
battery assessment scales refer to von Blanckenburg et al. (2013).
It would be important to compare these variables in RCTs (both
in the active medication group and in the placebo group) to
describe potential differences in these important aspects that may
be related to a possible negative treatment outcome (Amanzio
et al., 2012).
In the future, it would be interesting to test in prospective
RCTs the extent to which these specific variables would be related
to the presence/absence of AEs with an overall approach not yet
been developed, in order to take into account all these combining
factors (Amanzio et al., 2012). This will help to clarify the
presence of psychological distress predisposing patients to report
non-specific AEs to an even greater extent (Amanzio et al., 2012).
Moreover, arguing the nocebo phenomenon explicitly might
help patients to become more aware of self-fulfilling prophecies
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induced by misattribution. In this direction, a cognitive-
behavioral side effect prevention training by optimizing patients’
expectations was considered a potential pathway in health care to
improve a patients’ quality of life during long-term medication
intake (von Blanckenburg et al., 2013). This approach may be
useful in patients with stabilized schizophrenia. In line with
these suggestions, an assessment of the expectancies related
to treatment should be better developed to give an objective
measure of the individual predisposition (Younger et al., 2012).
With this purpose in mind, using an additional natural history
group as the trial’s so-called third arm is an important factor
that should be considered in RCTs (Amanzio, 2011). As to the
third group, it would be possible to study the AEs because of the
nocebo effects as the difference between the symptoms collected
in the natural history group and the side effects presented
in the placebo group (Amanzio, 2011). Indeed, natural course
conditions should be incorporated more frequently in RCTs,
such as in Zelen Design. This lets the disease natural history to
be monitored without randomizing patients to a no treatment
controls group to overcome ethical issues (Enck et al., 2013).
CONCLUSIONS AND IMPLICATIONS
This review of the placebo arm of RCTs of SCD patients
indicates that nocebo-related AEs may be substantial. Although
our research has been carefully design, some methodological
shortcomings may have played an important role in the results
observed. The first aspect concerns the literature search, in
which potential studies have been identified. The second aspect
concerns the meta-analytic experimental group heterogeneity
(different for age and gender), which could be another possible
confounding factor. The third aspect regards the original
adopted AEs classifiers and assessment methodology. The fourth
aspect—as before mentioned—concerns the meta-regression
approach itself.
Because an important recognized feature of meta-
analyses is that their results are critically dependent on the
quality and homogeneity of the individual studies analysed
(Papadopoulos and Mitsikostas, 2012), based on the general
nocebo effect literature of specific neurological diseases,
it is possible to suggest the inclusion of methodological
assessment in clinical trial designs, which may contribute
to the homogeneity of the population, and to tailor
individualized treatment in patients having chronic diseases
(Amanzio et al., 2016).
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